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ABSTRACT   
Global gene expression profiling of highly purified 5q deleted CD34
+CD38
-Thy1
+ 
cells in 5q- myelodysplastic syndromes (MDS) supported that they might originate 
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from and outcompete normal CD34
+CD38
-Thy1
+ hematopoietic stem cells. Few but 
distinct differences in gene expression distinguished MDS and normal stem cells. 
Expression of BMI1, encoding a critical regulator of self-renewal was up-regulated in 
5q- stem cells. Whereas multiple previous MDS genetic screens failed to identify 
altered expression of the gene encoding the myeloid transcription factor CEBPA, 
stage specific and extensive down-regulation of CEBPA was specifically observed in 
MDS progenitors These studies establish the importance of molecular characterization 
of distinct stages of cancer stem and progenitor cells to enhance the resolution of 
stage-specific dysregulated gene expression.   
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Introduction 
Although the existence of cancer stem cells (CSCs), in particular leukemic 
stem cells (LSCs), has been established for more than a decade
1,2, fundamentally 
important questions remain unanswered, relating to the exact identity and normal 
cellular origin of human CSCs, knowledge likely to have major impact towards a 
better understanding of the evolution, prognosis and therapeutic targeting of CSCs.  
Hematopoietic stem cells (HSCs) possess life long self-renewal capacity, and 
are therefore at high risk of acquiring the multiple mutations thought to be required 
for ultimate leukemic transformation. However, conclusive evidence for a normal 
HSC origin of LSCs would require proof of clonal involvement of all blood cell 
lineages derived from the multipotent HSCs. However, as yet, it has only been 
possible to obtain direct evidence for multilineage involvement in myeloproliferative 
disorders
3,4. Although this could mean that leukemias rarely originate in normal HSCs 
or multipotent progenitors, it is as possible that it in most cases is not feasible to prove 
through this approach, as most leukemias are lineage restricted in nature. Specifically, 
it is likely that a transforming event in a HSC will not only promote the development 
of the dominating leukemic lineage, but simultaneously also suppress the 
development of other lineages
5.  
An alternative and novel approach would rather be to apply genomics to better 
identify the origin of LSCs. As normal HSCs have been highly purified and found to 
have a distinct gene expression profile when compared to normal progenitors
6,7, a 
similar approach should be possible to better establish whether LSCs have a stem or 
progenitor cell identity. It would however require the identity of the LSC population 
to be well established, as well as conclusive evidence for a high clonal involvement of 
the purified LSCs to be investigated.  So far, these criteria would be fulfilled only in 
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rare cases, one being myelodysplastic syndromes (MDS) or preleukemia, a group of 
clonal malignant hematopoietic disorders, which frequently progress to acute myeloid 
leukemia (AML)
8. In patients with 5q- syndrome, a distinct clinical subgroup of 
MDS, characterized by an isolated deletion of the long arm of chromosome 5 (del(5q) 
or 5q-
9, we recently demonstrated that the 5q- stem cells resides in the minor 
CD34
+CD38
- Thy1
+ compartment, with definitive evidence for clonal myeloid as well 
as B lymphoid involvement in some patients, suggesting that 5q- syndrome at least in 
part originates at a multipotent stem/progenitor cell level
10,11. However, in most 
patients no evidence was obtained for B cell involvement and T cell involvement 
could never be established. 
In the present studies we purified and performed global gene expression 
profiling of normal and 5q- CD34
+CD38
-Thy1
+ cells
12,13, typically representing 0.1% 
of the total MDS bone marrow (BM) cells, and CD34
+CD38
+Thy1
- progenitors. This 
approach allowed us in all investigated cases to implicate the 5q- syndrome as a likely 
true HSC disease, and to establish stage specific dysregulated gene expression.  
 
Patients, material, and methods 
 
Patient samples  
BM samples from 11 MDS patients with typical 5q- syndrome
9  (Table 1) and from 10 healthy subjects 
were collected at the Hematology Departments at Karolinska (Solna), Karolinska (Huddinge), South 
Hospital, Helsingborg, and Lund University Hospitals, Sweden. The investigation was approved by the 
Research Ethics Committees at the respective University Hospitals, and informed consent was provided 
according to the Declaration of Helsinki. The MDS patients were chosen based on the finding of an 
isolated del(5q) by conventional cytogenetic analysis in combination with clinical and morphologic 
characteristics typical for the 5q-syndrome (an indolent clinical course with macrocytic anemia and a 
variable need for red blood cell transfusions, normal to elevated platelet counts, normal to slightly 
For personal use only. on November 7, 2014.  by guest    www.bloodjournal.org From   5
reduced WBC counts, hypolobulated megakaryocytes, and less than 5% blasts in the BM) resulting in 
MDS RA (FAB) and a 5q- syndrome (WHO) diagnosis and a low risk score according to the 
International Prognostic Scoring System (IPSS), for included patients. Patients #2, #6 and #9 had been 
treated unsuccessfully with EPO, patient #10 and #11 had ongoing EPO-treatment and six of 11 
patients needed erythrocyte transfusions regularly (Table 1).  
 
Purification of BM cell populations 
BM MNCs were isolated by Lymphoprep (Nycomed, Oslo, Norway) gradient centrifugation. Positive 
selection of CD34
+ BM cells was performed using a MACS (magnetically activated cell sorting) CD34 
isolation kit (Miltenyi Biotec, Bergish Gladbach, Germany) as previously described
11. The mean purity 
of enriched CD34
+ cells was 81%. Normal and 5q- MNC or CD34
+ cells were cryopreserved in 10% 
dimethylsulfoxid (DMSO) (Merck, Darmstadt, Germany) and 50% fetal calf serum (FCS; 
BioWhittaker, Walkersville, MD), and thawed swiftly in 37°C water bath, washed twice in Dulbecco´s 
phosphate buffered saline (PBS; PAA Laboratories, Pasching, Austria), and 5% FCS before staining. 
The CD34 enriched cells were incubated with CD38-allophycocyanin (APC), CD34-fluorescein 
isothiocyanate (FITC), and Thy-1 (CD90)-phycoerythrin (PE) monoclonal antibodies. The 30% CD34
+ 
cells expressing the highest levels of CD38 and lacking expression of Thy-1 (CD34
+CD38
+Thy-1
-) and 
the 5% CD34
+ cells with the lowest expression of CD38 and co-expression of Thy-1 (CD34
+CD38
-
Thy-1
+) were sorted on a FACSDiVa (Becton Dickinson). All samples were stained with 7-amino-
actinomyocin D (7-AAD; Sigma, St Louis, MO) to exclude non-viable cells. Both sorted populations 
reproducibly had a purity of more than 98% with regard to all three antigens. All antibodies were from 
BD Pharmingen (San Jose, CA) unless otherwise indicated. 
 
Hematopoietic growth factors 
Recombinant human (rh) granulocyte colony-stimulating factor (G-CSF), rh stem cell factor (SCF), rh 
interleukein-3 (IL-3), and rh granulocyte-macrophage colony-stimulating factor (GM-CSF) were 
generously provided by Amgen Corp. (Thousand Oaks, CA). Rh erythropoietin (Epo) was supplied by 
Boehringer Mannheim Corp. (Mannheim, Germany), thrombopoietin (Tpo) by Genentech (San 
Fransisco, CA), and rh flt3 ligand (FL) by Immunex (Seattle, WA). 
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Long-term culture-initiating cell (LTC-IC) assay 
Murine stromal feeders engineered to produce human growth factors (M2-10B4 and Sl/Sl mixed 1:1; 
kindly provided by Dr D.E. Hogge, Vancouver, Canada) were used to support growth of LTC-ICs as 
previously described
11. Cultures were established in 96-well collagen-coated microtiter plates with 
5,000 cells/well of each cell line, after irradiation with 8000 cGy, and cultured in long-term culture 
medium (MyeloCult H5100; Stem Cell Technologies) with 10
-6 M hydrocortisone 21-hemisuccinate. 
75-750 CD34
+CD38
+Thy-1
- and 75-750 CD34
+CD38
-Thy-1
+ cells from MDS patients and healthy 
subjects were added to the stroma layers, and co-cultures were maintained at 37° C in high humidity 
and with 50% medium exchange every week, as previously described (4). After 6 weeks, non-adherent 
and adherent cells were plated in methylcellulose cultures, supplemented with SCF, GM-CSF, G-CSF, 
FL, IL-3 (all at 10 ng/mL), and Epo (5 U/mL). Colony-forming cells (CFCs; read-out of LTC-IC assay) 
were scored after an additional 12 days in culture. Individual colonies were then picked and transferred 
to slides for subsequent FISH analysis. 
 
FISH probes and analyses 
Interphase FISH analyses, using probes hybridizing to 5q31 [SpectrumOrange LSI EGRI] and 5p15.2 
[SpectrumGreen LSI D5S721:D5S23] were performed essentially as described previously
10. All probes 
were obtained from Abbott (Stockholm, Sweden), and the signals were analyzed with the Chromofluor 
System (Applied Imaging, Newcastle, UK). The number of nuclei analyzed varied depending on the 
number of available cells, but whenever possible at least 200 nuclei were analyzed per cell population. 
In the nuclei of normal cells, the probes appear as 4 distinct signals, 2 orange and 2 green, whereas 
patients with del(5q) typically show 1 orange and 2 green signals. Based on FISH analyses on control 
cytospin preparations, the cut-off value (median + 2SD) for del(5q) was 6.2%. However, taking the 
purity of the sorted populations into account (>98%), findings of less than 10% del(5q) were 
considered to be negative or inconclusive. 
  
Purification of total RNA 
Normal and MDS CD34
+CD38
+Thy-1
- and CD34
+CD38
-Thy-1
+ cells were sorted directly into RLT 
lysis buffer (Qiagen, Hilden, Germany) and snap frozen at -80°C immediately after the sorting 
procedure. Samples were then thawed and, after homogenization by vortexing, total RNA was purified 
For personal use only. on November 7, 2014.  by guest    www.bloodjournal.org From   7
from 1×10
4 CD34
+CD38
+Thy-1
- and CD34
+CD38
-Thy-1
+ cells with RNeasy Micro Kit (Qiagen) 
following the manufacturer’s protocol for isolation of RNA from animal cells including the optional 
on-column DNase treatment.  
 
Double linear amplification of total RNA and probe preparation 
Before amplification, 200 ng of Poly (dI-dC) (Sigma, St Louis, MO) was added as nucleic acid carrier 
to each sample of total RNA. The total RNA isolated from 1×10
4 CD34
+CD38
+Thy-1
- and 
CD34
+CD38
-Thy-1
+ cells was double linear amplified with a combination of RiboAmp OA RNA 
Amplification Kit (Arcturus, Mountain View, CA) for the first round of amplification and the following 
generation of double stranded cDNA, and Low RNA Input Flourescent Linear Amplification Kit 
(Agilent, Palo Alto, CA) to generate the second round amplified labeled aRNA, following the 
manufacturer’s protocols. A pool of double linear amplified labeled Universal Human Reference RNA 
(Stratagene, La Jolla, CA) was used as reference to all samples at the hybridization. Samples were 
labeled with Cy3-CTP (PerkinElmer, Boston, MA) and reference reactions with Cy5-CTP 
(PerkinElmer). A nanodrop Spectrophotometer (NanoDrop Technologies, DE) was used to determine 
the dye concentration, and appropriate amounts of sample and reference aRNA were combined, 
lyophilized to dryness in an Eppendorf Concentrator (Eppendorf AG, Germany) and stored at -80°C.  
 
Preparation and printing of oligonucleotide microarrays 
Oligonucleotide microarrays were produced by the Swegene DNA Microarray Resource Center, 
Department of Oncology, Lund University, Sweden (http://swegene.onk.lu.se; Swegene Center Home 
page). Array ready oligolibraries Human Genome Oligo Version 2.1 (containing 21,329 70mer probes, 
Cat. No. 810518) and Human Genome Oligo Set Version 2.1 Upgrade (containing 5,462 70mer probes, 
Cat. No. 810518) were obtained from Operon (Biotechnologies Inc., Alabama). Lyophilized probes 
were re-suspended in Pronto! Universal Spotting solution (Corning Incorporated, Corning, NY) to a 
concentration of 24 mM. The entire probe set, in addition to a number of positive and negative controls, 
was printed in duplicate on aminosilane coated UltraGAPS slides (Corning Incorporated) using a 
BioRobotics MicroGrid2 R600 robot (Genomic Solutions, MI) equipped with MicroSpot 10K quill 
pins (Genomic Solutions, MI). Printing was performed in a temperature (18-20°C) and humidity (44-
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49% RH) controlled area, and the printed slides were left in a vacuum dessicator to dry for at least 48 
hours before use. 
 
Hybridization, image processing and image acquisition   
Microarray slides were re-hydrated over steaming water for 1-2 seconds, snap dried on a hot plate 
(98°C), and then UV cross-linked (800mJ/cm
2) using a Stratalinker (Stratagene). Pre-hybridization 
treatment, hybridization, and post-hybridization washes of slides were performed according to the 
manufacturers´ protocols provided with the Universal Microarray Hybridization Kit (Corning 
Incorporated). In short, the array slides were pre-soaked with a sodium borohydride reducing solution, 
pre-hybridized with a BSA containing solution, washed, and dried by centrifugation. Prepared labeled 
aRNA was re-suspended in hybridization solution and incubated at 65°C for 5 minutes and then cooled 
to ambient temperature before it was applied to the array and covered with a glass cover slip. The array 
slides were hybridized in Corning hybridization chambers (Corning Incorporated) at 42°C during 17-20 
hours, washed, and finally dried by centrifugation.  
The Agilent G2565AA Microarray Scanner (Agilent Technologies) was used to measure the 
fluorescence intensities at PMT gain 100%, and at 10 um pixel resolution, data were collected at two 
different wavelengths (for Cy3 and Cy5) and stored as multi TIFF images and analyzed by using the 
GenePix
TM Pro 4.1.1 software (Axon Instruments Inc., Foster City, CA) with standard flagging criteria.  
Quantified data matrix from GenePix was saved as a GenePix Results File (gpr) and loaded into the 
Bio Array Software Environment (BASE) for further data analysis. Background subtraction for Cy3 
and Cy5 intensities were calculated using the median spot pixel intensity and median local background 
intensity provided in the GenePix result file.                                                                                          
     
Data extraction   
In an initial spot quality filter, spots flagged by the criteria above, with a diameter of 40 pixels or less, 
an intensity of 0 units or less in either channel, or 10% or more saturated pixels in either channel, were 
removed. Intensity dependent lowess
14 fits were used to normalize intensity ratios on each assay. For 
each spot, the uncertainty of the expression value was estimated as u=(SNR1)-2+(SNR2)-2, where 
SNRi is the signal to background noise ratio for channel i. Replicate measurements of the same reporter 
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on an assay were merged and represented by a weighted mean. The weighted mean of a set of values xi 
was defined as m=Σiwixi /Σiwi where the weight wi is exp(-3ui1/2/|xi-m|). This set of equations was 
solved numerically by simple iteration. The error of the merged value was defined as 
U=1/Σi(1/ui)+Σiwi2(xi-m)2/(Σiwi)2. All reporters with GenBank accession number or RefSeq specified 
were associated to genes using ACID 
15. The four different types of assays (normal and 5q- 
CD34
+CD38
+Thy-1
- progenitors and CD34
+CD38
-Thy-1
+ stem cells) were compared pair-wise in 
different ways, and for each comparison, the error model, presence filter (requiring 85% presence), and 
variation filter described above were applied to the assays involved, resulting in an optimal data 
extraction for each comparison. Association was based on UniGene Homo Sapiens build 176. 
Expression values for reporters representing the same gene were merged in the weighted fashion 
described above. Reporters without association to a known gene were excluded from the analysis. The 
merged data were transformed again to a modified expression value xi'=wi (xi-m). A presence filter and 
a variation filter across assays were also applied to the data, keeping only spots with expression in both 
channels in at least 21 of 23 assays, and with a standard deviation of modified expression values greater 
than 0.3. The 23 assays represented 18 different samples, of which three were done in duplicate and 
one in triplicate. Hierarchical clustering revealed that replicate assays ended up in the same cluster 
(data not shown). This means that the experimental variability was small compared to differences 
between assay types, though not significantly smaller than variations among assays of the same type, 
which may indicate large homogeneity within the assay types. As the rest of the study concerns 
comparisons of different types, replicates were merged in the weighted fashion described above before 
continued analysis. 
 
Statistical analysis 
As a measure of difference between two types of assays, we used the false discovery rate in ranked 
gene lists. In each of the pair-wise comparisons described above, the genes that passed the filters were 
ranked according to the Fisher linear discriminant; F = (m1 – m0) / (σ1
2 + σ0
2)1/2, where m1 and m0 
are the (unweighted) mean values for subgroups 1 and 0, respectively, whereas σ1 and σ0 are the 
standard deviations for the same subgroups. A permutation test with all possible permutations of 
sample labels was performed, and for each score, the average number of genes in a permutation list 
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above that score was divided by the number of genes in the true list above to get the false discovery 
rate.  
 
Quantitative-RT-PCR (Q-PCR) 
10,000 BM CD34
+CD38
-Thy-1
+ and CD34
+CD38
+Thy-1
- cells were sorted directly into 330 µL RLT 
lysis buffer (Qiagen) and snap frozen at -80°C. RNA extraction and DNase treatment were performed 
with the RNeasy Micro kit (Qiagen) according to the manufacturer’s instructions for samples 
containing  ≤105 cells. Eluted RNA samples were reverse transcribed using  SuperScript  II 
TM and 
random hexamers (Invitrogen) according to the protocol supplied by the manufacturer. Newly 
synthesized cDNA was diluted to approximately contain cDNA from 50 cells/µl and frozen at -20°C. 
Q-PCR reactions were performed by mixing 2×TaqMan universal PCR master mix, 20× Assays-on-
Demand
TM (primer/MGB-probe mix), RNase-free H2O, and 5µl of cDNA to a final reaction volume of 
20 µL. The TaqMan Assays-on-Demand
TM probes used are described in Supplementary methods. All 
experiments were performed in triplicates, and differences in cDNA input were compensated by 
normalizing against HPRT expression levels. The TaqMan Assays-on-DemandTM probes used were 
AREG: Hs00155832_m1, BMI1: Hs00180411_m1, CDC42SE2: Hs00184113_m1, CEBPΑ: 
Hs00269972_s1, CTNNA1: Hs00426996_m1, CTNNB1: Hs00170025_m1, DLK1: Hs00171584_m1, 
HLF: Hs00171406_m1, HPRT1: Hs99999909_m1, IFITM1: Hs00705137_s1, and TAF7: 
Hs00538821_s1, (all from Applied Biosystems, California) 
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Results 
Extensive clonal involvement of the CD34
+CD38
-Thy-1
+ HSC compartment and 
replacement of normal HSCs in 5q- syndrome 
The size of the CD34
+CD38
-Thy1
+ HSC compartment in 11 patients with 5q- 
syndrome
9, represented on average 0.14% of total BM cells, only slightly increased 
over healthy individuals (mean 0.04%; Table 1 and Figure 1). Notably, as much as 92-
100% of the CD34
+CD38
-Thy1
+ cells were part of the 5q- clone.  
The content of functionally defined normal and MDS long-term culture-
initiating cells (LTC-IC), as an assay for stem cell activity 
16,17, was next investigated 
in 4 patients.  Although MDS BM cells, reflecting MDS being a disease of inefficient 
hematopoiesis, in almost all cases fail to long-term reconstitute MDS in immune-
deficient mice in vivo
18, we have previously demonstrated that MDS-initiating LTC-
IC activity, when detected, is exclusively contained within the minor CD34
+CD38
- 
HSC compartment
10,11,18. In agreement with this, in two of the 4 investigated patients 
with 5q- syndrome we detected LTC-IC activity, and this was exclusively derived 
from CD34
+CD38
-Thy1
+ cells (Table 2), despite investigating up to 10-fold more 
CD34
+CD38
+Thy-1
-  cells. Noteworthy, all LTC-CFC generated from 5q- 
CD34
+CD38
-Thy1
+ BM cells were shown to harbor the del(5q) (Table 2). Thus, 
neither CD34
+CD38
-Thy1
+ nor CD34
+CD38
+Thy1
- cells from 5q- patients displayed 
detectable normal HSC activity, supporting that the normal HSC compartment in 5q- 
syndrome patients has been replaced by a clonally expanded 5q- compartment with 
the same CD34
+CD38
-Thy1
+ phenotype.  
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Global gene expression profiling implicates that the 5q- syndrome initiates in 
normal CD34
+CD38
-Thy1
+ HSCs. 
Although MDS stem cells share a CD34
+CD38
-Thy1
+ phenotype with normal HSCs  
1,10,13,19,
 this does not necessarily mean the malignancy initiated in normal HSCs, as it 
might rather reflect acquisition of a stem cell cell surface phenotype by a transformed 
MDS progenitor
19. Thus, we here used a novel global gene profiling strategy, in an 
attempt to distinguish better between a stem and progenitor cell identity of the 5q- 
stem cells, taking advantage of the distinct gene expression patterns of normal HSCs 
and progenitors
6. 
While no previous studies have performed a global gene expression profiling of 
CD34
+CD38
-Thy1
+ BM cells, Georgantas et al. (2004) reported genes significantly 
up- or down-regulated in normal BM CD34
+CD38
-Lin
- HSCs, compared to 
CD34
+CD38
+Lin
+ progenitor cells. We extracted data from our normal CD34
+CD38
-
Thy-1
+ and CD34
+CD38
+Thy-1
- datasets, ranked genes using Fisher linear 
discriminant scores
20 and found a high degree of agreement with the data set of 
Georgantas et al. (2004) (Supplementary Figure 1), in which 1,190 reporters were 
found to be significantly up-regulated in CD34
+CD38
-Lin
- cells. We updated all gene 
identities for these reporters according to UniGene build 176 
[http://www.ncbi.nlm.nih.gov/UniGene/], and found that 276 genes were present also 
in our list after filtration. Of those, 197 had positive Fisher scores in our data set. 
Eight of the 276 genes were found among our 20 most up-regulated genes, whereas 
the other twelve were not mentioned. To further evaluate the overall agreement, using 
our whole ranked list, we calculated the area under the Receiver Operating 
Characteristic (ROC)-curve
21, which is a linear transformation of the Wilcoxon rank 
sum
22. The ROC area for the 276 genes up-regulated in CD34
+CD38
-Lin
- cells was 
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0.73 (Supplementary Fig. 1), with a p-value of 10
-37 [random gene permutations]. 
Similarly, the 1,159 reporters found down-regulated by Georgantas et al. (2004), were 
associated to genes using UniGene build 176, and 374 of the genes were found in our 
ranked list as well. Turning our ranked list upside-down, so that down-regulated genes 
received top-ranks, we found that eleven of our top 20 down-regulated genes were 
down-regulated in the studies of Georgantas at al (2004) as well, whereas the other 
nine were not mentioned.  The ROC area was 0.82, with a p-value of 10
-93 
(Supplementary Fig. 1). The complete list of genes differentially expressed between 
normal CD34
+CD38
-Thy-1
+ and CD34
+CD38
+Thy-1
- cells is available in 
Supplementary Table 1.  
We next compared the global expression profiles of CD34
+CD38
-Thy-1
+ MDS 
stem cells from four 5q- syndrome patients (#1, #2, #3, and #5), with those of 
CD34
+CD38
-Thy-1
+ and CD34
+CD38
+Thy-1
- cells from 5 healthy subjects. Notably, 
the number of differentially expressed genes was considerably less when comparing 
5q- CD34
+CD38
-Thy-1
+ cells to normal CD34
+CD38
-Thy-1
+ cells, than when 
comparing to normal or 5q- CD34
+CD38
+Thy-1
- progenitors (Figure 2). Furthermore, 
the Fisher scores of 5q- CD34
+CD38
-Thy-1
+ compared to normal CD34
+CD38
-Thy-1
+ 
cells were comparable to the random expectation, represented by permutation test 
results (Methods), demonstrating a very close identity between normal and 5q- 
CD34
+CD38
-Thy-1
+ cells (Figure 2a-b). 
The false discovery rate was high when comparing 5q- CD34
+CD38
-Thy-1
+ 
cells with normal CD34
+CD38
-Thy-1
+ cells, but essentially zero when compared to 
normal CD34
+CD38
+Thy-1
-  progenitors (Figure 1c), further reflecting the high 
similarity between 5q- and normal CD34
+CD38
-Thy-1
+ cells.  
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Differentially expressed genes in 5q deleted CD34
+CD38
-Thy1
+ stem cells  
To confirm the expected down-regulation of genes located at 5q31q32 we investigated 
37 such genes found in our lists, of which 34 were down-regulated in CD34
+CD38
-
Thy-1
+ cells in at least 3 of the 4 investigated patients (Supplementary Table 2).  
Based on the array data, a total of ten potentially interesting genes were 
investigated in further detail using Q-PCR analysis, in part to confirm and quantify 
better some of the array findings on CD34
+CD38
-Thy-1
+ cells (patients #1 and #2), 
and in part to extend the analysis to additional patients. Table 3 shows array data on 
selected genes that were up- or down-regulated with high Fisher scores in 5q- 
CD34
+CD38
-Thy-1
+ cells (complete list of genes in Supplementary Table 3).   
Importantly, the Q-PCR analyses of patients #1 and #2 confirmed all array findings.  
In all patients investigated by Q-PCR, all three examined genes situated on the 
involved region of 5q (TAF7 at 5q31, CDC42SE2 at 5q23, and CTNNA1 at 5q31) 
were, as expected, down-regulated in CD34
+CD38
-Thy-1
+ cells (Figure 3). Thus, 
TAF7
23, CDC42SE2
24, and CTNNA1 (alpha catenin; implicated in the Wnt signaling 
pathway as a tumor suppressor gene)
25, were all down-regulated by approximately 
50% (46%,46%, and 55% respectively) (Figure 3). However, the functionally related 
CTNNB1 (beta catenin)
26, implicated in the regulation of normal and leukemic HSC 
self-renewal
27 (not located at 5q), was not significantly affected in investigated 
patients (Figure 3). 
HLF, a transcription factor involved in t(17;19)/TCF3-HLF (previously E2A-
HLF)-positive acute lymphoblastic leukemia (ALL)
28, reported to be specifically 
expressed in normal human HSCs
6, was down-regulated in all 7 patients investigated 
(5 by Q-PCR and 2 additional by array) by a mean of 3.2-fold. Interferon-induced 
transmembrane protein-1 (IFITM1), suggested to play a role in the antiproliferative 
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activity of interferons
29, was up-regulated in all 7 investigated patients, in the five 
investigated by Q-PCR by a mean of 5.3-fold, whereas Amphiregulin (AREG), an 
apoptosis inhibitor
30, was down-regulated in all 7 patients, by as much as 10-fold or 
more (Figure 3). 
Delta–like homolog (DLK1), involved in Notch signaling
31, was by Q-PCR 
analysis found to be up-regulated 1.5–12.6 fold in 6 of 9 patients investigated by Q-
PCR (Figure 3).  
Of particular interest, BMI1, critically involved in regulation of HSC self-
renewal
32,33 was up-regulated in all but one of nine patients analyzed by Q-PCR, by a 
mean of 2.5-fold (Figure 3). 
CCAAT enhancer binding protein-alpha (CEBPA), essential for normal 
myeloid development and implicated in the transformation of AML
34,35, was in the 
array analysis up-regulated in all 4 patients (#1, #2, #3, and #5). This was confirmed 
by Q-PCR for two patients (#1 and #2) and extended to an additional 2 patients (#4 
and #6). However, in four other patients (#8, #9, #10, and #11), the expression was 
not significantly different from normal CD34
+CD38
-Thy-1
+ cells and in one patient 
(#7) rather down-regulated. 
 
Enhanced resolution of dysregulated gene expression in purified CD34
+CD38
-
Thy-1
+ stem and CD34
+CD38
+Thy-1
- progenitor cells with del (5q) 
To evaluate the potential benefit of global gene profiling of purified and 
distinct MDS stem and progenitor cell populations, rather than mixed populations
36-39, 
and thereby also identification of stage-specific changes in gene expression, we next 
compared differentially expressed genes between purified 5q- and normal 
CD34
+CD38
-Thy-1
+  stem cells and between 5q- and normal CD34
+CD38
+Thy-1
- 
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progenitors (Figure 4). Whereas 5q- and normal CD34
+CD38
+Thy-1
-  progenitors 
showed a relatively high number of differentially expressed genes, much fewer and 
smaller differences were observed when comparing the profiles of normal and 5q- 
CD34
+CD38
-Thy-1
+ stem cells
  (Figure 4a-b).   
Strikingly, expression of CEBPA, which was either up-regulated or normal in 
CD34
+CD38
-Thy-1
+  cells in
  most 5q- patients (Figure 3 and 4c-d), was rather 
consistently and dramatically down-regulated in 5q- CD34
+CD38
+Thy-1
- progenitors 
(Figure 4c-d), as determined by microarray analysis. CTNNA1, BMI1 and DLK1 were 
also differentially affected in the 5q- CD34
+CD38
+Thy-1
+ stem and 
CD34
+CD38
+Thy-1
- progenitor populations (Figure 4c), whereas other investigated 
genes (TAF7, CDC42SE2, HLF, IFITM1 and AREG), showed a similar pattern of 
expression between CD34
+CD38
-Thy-1
+ and CD34
+CD38
+Thy-1
- cells (Figure 4c).  
In contrast to recent studies
40 we did not find CTNNA1 to be downregulated 
more than the expected 50%, perhaps reflecting that the reported hypermethylation of 
CTNNA1 in patients with 5q deletions, might be a late event not typically observed in 
patients with 5q-syndrome.  
Nine patients were investigated by Q-PCR to confirm and extend the 
contrasting expression of CEBPA  in 5q- CD34
+CD38
-Thy-1
+ stem and 
CD34
+CD38
+Thy-1
- progenitor cells. Noteworthy, when compared to their normal 
counterparts,  CEPBA was dramatically down-regulated in all nine investigated 
patients (range 2.2–1236 fold) in 5q- CD34
+CD38
+Thy-1
- progenitors, but not in 
CD34
+CD38
-Thy-1
+ stem cells (Figure 4d). Although CEBPA was in one case (#7) 
down-regulated (4.3-fold) in 5q- CD34
+CD38
-Thy-1
+ cells, its expression was 
reduced even more in 5q- CD34
+CD38
+Thy-1
- progenitors (as much as 1236-fold) 
when compared to normal CD34
+CD38
+Thy-1
- progenitors (Figure 4d). 
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Discussion 
The present studies exemplify the importance of performing global gene expression 
profiling of purified cancer stem and progenitor cell populations. Not only did the 
molecular fingerprinting of 5q- CD34
+CD38
-Thy-1
+ cells provide stronger support for 
5q- syndrome potentially originating from normal HSCs, it also resulted in a much 
higher resolution of specific gene expression changes when comparing MDS and 
normal stem and progenitor cells, rather than more heterogeneous populations
36-39.  
Although it has been postulated that LSCs and other CSCs frequently may 
originate in the corresponding rare normal multipotent stem cell populations
19,41, 
conclusive evidence for such a model has only been obtained for myeloproliferative 
disorders
3,4. In other leukemias the evidence has at best been circumstantial, typically 
limited to the leukemic and normal stem cells sharing a CD34
+CD38
- cell surface 
phenotype
42. However, the expression of CD34 and CD38 antigens, although 
instrumental for identification of normal HSCs in steady state hematopoiesis
13, has in 
mice as well as in humans been demonstrated to fluctuate considerably
43,44. 
In the current studies, we adopted a novel approach applying genomics to 
better determine the identity of the 5q- stem cell population. In all investigated 
patients, >92% of CD34
+CD38
-Thy1
+ cells were shown to harbor the del(5q), 
demonstrating that virtually all the cells in the CD34
+CD38
-Thy1
+ compartment of 
these patients are part of the MDS clone. The 5q- CD34
+CD38
-Thy1
+ compartment 
represented 0.14% of all BM cells, being only slightly expanded when compared to 
the CD34
+CD38
-Thy-1
+ HSC compartment in healthy subjects, demonstrating that the 
normal CD34
+CD38
-Thy1
+ HSC compartment had almost completely been replaced 
with 5q- stem cells, a conclusion further substantiated by the lack of detectable 
normal LTC-IC activity in all investigated patients. Thus, 5q- CD34
+CD38
-Thy1
+ 
For personal use only. on November 7, 2014.  by guest    www.bloodjournal.org From   18
cells appear to largely outcompete and hence deplete their normal counterparts, a 
finding also supported by up to 99% of granulocytes in these patients being 5q 
deleted
10. However, the mechanisms or niches that are in place to limit the size of the 
normal HSC pool
45,46 appear also to be able to restrict the size of the 5q- HSC 
compartment at this stage of the disease (up to 8 years after diagnosis).  
In two of the four investigated 5q- patients we observed 5q- LTC-CFC activity 
from CD34
+CD38
-Thy1
+ but not CD34
+CD38
+Thy-1
-  cells, supporting  that the 
infrequent 5q- CD34
+CD38
-Thy1
+ cells are the MDS stem cells in these patients. 
However, in two other patients in which we also observed a virtually complete 
replacement of the normal CD34
+CD38
-Thy1
+ compartment with 5q- CD34
+CD38
-
Thy1
+ cells, we failed to detect not only normal but also 5q- LTC-CFC activity. 
Although we could show also in these patients that normal HSCs have been out-
competed by 5q- MDS stem cells, the functional data failed in these cases to 
conclusively show that 5q- CD34
+CD38
-Thy1
+ cells are in fact the MDS stem cells. 
The most likely interpretation of the lack of 5q- LTC-CFC activity in these two 
patients is that the readout of this assay requires efficient myeloid differentiation from 
investigated HSC populations, which is variably affected in MDS.  
Strikingly, 5q- and normal CD34
+CD38
-Thy1
+ stem cells showed an almost 
perfect match in global gene expression patterns, as the Fisher scores were low and 
comparable to the random expectation. In contrast, 5q- CD34
+CD38
-Thy1
+  cells 
displayed extensive differences to normal as well as 5q- CD34
+CD38
+Thy1
- 
progenitors. Thus, the gene expression pattern of 5q- CD34
+CD38
-Thy1
+ cells further 
supports that the 5q- syndrome might initiate in the normal CD34
+CD38
-Thy1
+ HSC 
compartment, even though an origin in an even more primitive, not yet identified cell 
population can not be ruled out. Although previous studies suggested the possibility 
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of a HSC origin of 5q- syndrome, by demonstrating involvement of B cells in a few 
patients
10,47, the present results are compatible with most, if not all, 5q-syndromes 
potentially originating in the HSC pool. As LSCs and other CSCs typically will be 
biased in their differentiation towards one particular lineage, and inefficient or 
incapable of generating other lineages, we predict that global gene expression 
profiling will become an important complementary tool for determining the cellular 
origin of LSCs as well as other CSCs. Although our studies unequivocally establish a 
very close identity between normal and MDS stem cells, it can however not be ruled 
out that this could result from reacquisition of a stem cell phenotype of a targeted 
normal progenitor cell population, rather than origin in a normal HSC. 
The most salient finding in the present study, was the many and pronounced 
differences observed in gene expression between 5q- and normal CD34
+CD38
+Thy1
- 
progenitors, compared to the few but distinct differences detected between 5q- and 
normal CD34
+CD38
-Thy1
+ stem cells.  Previous global expression profiling studies 
on MDS cases have, at most been performed on CD34
+ or CD133
+ cells
36-39, 
containing both CD34
+CD38
-Thy1
+ stem and CD34
+CD38
+Thy1
- progenitor cells. 
The present approach allowed us to identify stage specific changes in gene expression.  
Multiple previous gene profiling studies of MDS (including 5q-) patients, had 
failed to find consistent changes in expression of CEBPA
36-39, despite of mouse 
studies implicating the potential involvement of reduced CEBPA expression in 
development of MDS
48. In contrast, in the present studies we found in all 9 
investigated 5q- patients that CEBPA was down-regulated in the MDS progenitors, at 
a minimum 2.2-fold. Our finding of consistently reduced CEBPA expression in 5q- 
progenitors, support an involvement of dysregulated CEBPA expression in the 
inefficient granulopoiesis characteristic of MDS
48.  
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BMI1 was preferentially up-regulated in 5q- CD34
+CD38
-Thy1
+ cells. 
Identified as an essential regulator of normal HSC self renewal, and involved in 
leukemogenesis if deregulated
32, the up-regulation of BMI1 could potentially explain 
the competitive advantage of 5q- CD34
+CD38
-Thy1
+ stem cells over normal HSCs.  
  In conclusion, the present studies highlight the importance of molecular 
characterization of distinct stages of cancer stem and progenitor cells to identify and 
characterize stage-specific dysregulated gene expression in cancer.   
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Table 1. Clinical, hematologic, and cytogenetic characteristics of the 5q- syndrome patients 
CD34
+CD38
+ cells  CD34
+CD38
-Thy-1
+ cells  No Sex/ 
age 
Years 
since 
diagnosis 
Hb 
g/l 
WBC 
10
9/l 
Plt 
10
9/l 
Ongoing 
treatment 
% of MNC  %FISH 5q-   % of MNC  %FISH 5q- 
1 F/83  3  96 3.3  374  E  1.50  100  (216)  0.16  99  (156) 
2  F/77  8  100  3.8  130  E 4.00 99  (262) 0.10  100  (43) 
3  F/54  1  108  6.1  231  E  0.60  100 (224)  0.01  96 (95) 
4  F/89  2  85  5.3  236  E  0.45  100 (221)  0.08  100 (145) 
5 F/60  1  120 9.2  1234  --  1.60  100  (244)  0.05  95  (264) 
6  F/58  4  122  3.3  448  E 3.20 99  (140) 0.08  99  (165) 
7  F/64  3  100  4.9  267  -- 3.20 98  (259) 0.11  92  (76) 
8  F/85  1  102  3.6  309  -- 0.50 93  (323) 0.09  98  (251) 
9  F/85  7  76  1.3  95  P 0.43 100  (47) 0.50  97  (73) 
10  F/82  3  103  6.4  443  EPO,  P  0.34 96  (24) 0.20  100  (51) 
11  F/86  8  129  4.7  204  EPO  1.50 nd 0.15  95  (40) 
                    
MDS mean [SEM]  104 [4.7]  4.7 [0.6]  361 [93]    1.57 [0.40]  98.5 [0.73]  0.14 [0.04]  97.4 [0.79] 
Normal mean† [SEM]  135 7.0  270    1.80 [0.20]  6.2*  0.04 [0.01]  6.2* 
 
BM morphology and blood values were investigated in connection with BM aspiration for the present studies. All patients were females and had a verified diagnosis of 5q- syndrome
15 
according to the WHO classification, with a typical BM morphology including hypolobular megakaryocytes and a low BM blast count (<5%; RA according to FAB classification), an 
isolated 5q deletion encompassing q13-q15 to q31-q35, normal to elevated platelet counts and normal to slightly reduced WBC. The relative frequencies of CD34
+CD38
+ and CD34
+CD38
-
Thy-1
+ cells were calculated from the number of BM MNC and the FACS profiles. Number of nuclei evaluated by FISH is given in parenthesis. If sufficient cells, at least 100-200 nuclei 
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were always counted. * Cut-off for FISH del(5q); median + 2SD. RA indicates refractory anemia; FAB, French-American-British; WHO, World Health Organization; BM, bone marrow; 
Hb, hemoglobin; WBC, white blood count; Plt, platelets; E, erythrocyte transfusions; EPO, erythropoietin; P, prednisolon.  
† (n =10) 
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Table 2. Normal and 5q- clonal LTC-IC activity of 5q- CD34
+CD38
+Thy-1
- and CD34
+CD38
-Thy-1
+ cells   
LTC-CFC/1000 cells 
CD34
+CD38
+Thy-1
- cells  CD34
+CD38
-Thy-1
+ cells 
 
 
Patient No  Normal 5q  deleted Normal 5q  deleted 
1 
2 
4 
6 
Normal mean (n = 5) 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
1838 
29 
0 
0 
51 
0 
 
Six-week LTC-CFC activity of CD34
+CD38
-Thy-1
+ (75-750 cells/well) and CD34
+CD38
+Thy-1
- (750 cells/well) cells from healthy controls and 5q- syndrome patients were 
evaluated as described in Experimental procedures. After six weeks of co-culture, the number of CFCs produced after an additional two weeks in methylcellulose were counted. 
Results are the means of 3-6 replicate wells from each patient and cell population. No LTC-CFCs were derived from normal or 5q- CD34
+CD38
+Thy-1
- candidate progenitor cells. 
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 Table 3. Differentially expressed genes in 5q- versus normal CD34
+CD38
-Thy-1
+ cells  
Gene name  Gene symbol  Accession  
Number 
Known function   Up/ 
down 
Fisher 
score 
Interferon induced transmembrane protein 1 
Serine/threonine kinase 19 
IFITM1* 
STK19 
NM_003641 
NM_032454 
Inhibition of cell proliferation 
Transcriptional regulation 
Up 
Up 
2.7 
2.5 
Kelch-like ECT2 interacting protein 
Kinesin family member 2C 
Growth arrest-specific 2 
Cytochrome b-245, beta polypeptide 
Solute carrier family 9 
Gp25L2 protein 
TAF5 RNA polymerase II 
Thiosulfate sulfurtransferase (rhodanese) 
Topoisomerase (DNA) II binding protein 
Golgin-67 
CHK2 checkpoint homolog (S.pombe) 
Enah/Vasp-like 
Cell division cycle associated 7 
CCAAT/enhancer binding protein (C/EBP), alpha 
Cell division cycle 25 B 
Polymerase (D directed), epsilon 2 (p59 subunit) 
CD99 antigen 
Bloom syndrome 
KLEIP 
KIF2C 
GAS2 
CYBB 
SLC9A3R1 
HSGP25L2G 
TAF5* 
TST 
TOPBP1 
GOLGIN-67 
CHEK2 
EVL 
CDCA7 
CEBPA* 
CDC25B 
POLE2 
CD99 
BLM 
NM_014458 
NM_006845 
NM_005256 
NM_000397 
NM_004252 
BC001123 
NM_006951 
NM_003312 
NM_007027 
AF204231 
NM_007194 
NM_016337 
NM_031942 
NM_004364 
NM_021874 
NM_002692 
NM_002414 
NM_000057 
Cytoskeleton organization 
Chromosome movements during cell division 
p53-dependent apoptosis 
Microbicidal phagocytic oxidative system 
Wnt  signaling  
Located at 5q35.3; Unknown function 
Transcriptional regulation 
Mitochondrial enzyme 
DNA damage response protein 
Golgi apparatus protein 
Putative tumor suppressor 
Cytoskeleton rearrangement and signal transduction 
C-myc target gene; lymfoblastoid cell transformation 
TF; neutrophil differentiation; mutated in AML 
Cell cycle regulator; Oncogenic properties 
DNA replication 
T cell apoptosis; involved in gastric adenocarcinomas 
Suppressor of inappropriate recombination. 
Up 
Up 
Up 
Up 
Up 
Up 
Up 
Up 
Up 
Up 
Up 
Up 
Up 
Up 
Up 
Up 
Up 
Up 
2.0 
2.0 
2.0 
1.9 
1.9 
1.9 
1.8 
1.8 
1.7 
1.6 
1.6 
1.6 
1.6 
1.5 
1.5 
1.5 
1.4 
1.4 
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Defective in sister chromatid cohesion homolog 1 
D (cytosine-5-)-methyltransferase 3, alpha 
Inhibitor of DNA binding 1 
Delta-like homolog 
Tumor protein p53 binding protein 1 
V-myc myelocytoma 
B lymphoma Mo-MLV insertion region 
Solute carrier family 25A, member 4 
Ribosomal protein S21 
Arachidonate 12-lipooxygenase, 12R type 
Amphiregulin schwannoma-derived growth factor) 
Hepatic leukemia factor 
TAF7 RNA polymerase II 
Pleckstrin homolog domain 
WAS protein family 
Myotrophin 
Glycoprotein Ib (platelet), beta-polypeptide 
Target of myb1-like 1 (chicken) 
F-box and leucin-rich repeat protein 5 
Activated leukocyte cell adhesion molecule 
Zinc finger protein 366 
Forkhead box O1A 
MADS box transcription enhancer factor 2 
DCC1 
DNMT3 
ID1 
DLK1* 
TP53BP1 
MYC 
BMI1* 
SLC25A4 
RPS21 
ALOX12B 
AREG* 
HLF* 
TAF7* 
PLEKHA6 
WASF3 
MTPN 
GP1BB 
TOM1L1 
FBXL5 
ALCAM* 
ZNF366 
FOXO1A 
MEF2C 
NM_024094 
NM_022552 
NM_002165 
NM_003836 
NM_005657 
NM_002467 
NM_005180 
NM_001151 
NM_001024 
NM_001139 
NM_001657 
M95585 
NM_005642 
BC010522 
AB020707 
AK055660 
L20860 
NM_005486 
NM_033535 
Y10183 
NM_152625 
NM_002015 
L08895 
Faithful inheritance of chromosomes to daughter cells 
De novo methylation 
Malignant progression 
Notch-related differentiation-associated 
Tumor suppressor gene 
Oncogene 
Implicated in HSC self-renewal 
Apoptosis inhibitor 
Component of the small 40S ribosomal subunit 
Iron ion binding 
Interacts with EGF/TGF-α; inhibits carcinoma 
TF involved in t(17;19) translocation in ALL 
Located at 5q31; Transcriptional regulation  
Signal transduction 
Member of the Wiskott-Aldrich syndrome protein family 
Regulation of NFκB 
Associated with Bernard-Soulier or giant platelet disorder 
Signal transduction 
Proteasome degradation 
Associated with tumor progression 
Located at 5q13.2; Transcriptional regulation 
TF; involved in malignant transformation 
Located at 5q14; Transcriptional regulation 
Up 
Up 
Up 
Up 
Up 
Up 
Up 
Down 
Down 
Down 
Down 
Down 
Down 
Down 
Down 
Down 
Down 
Down 
Down 
Down 
Down 
Down 
Down 
1.4 
1.4 
1.2 
1.1 
1.0 
1.0 
0.9 
2.4 
2.2 
1.9 
1.8 
1.7 
1.7 
1.7 
1.7 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.5 
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CREBB/EP300 inhibitor 1 
Endoplasmic reticulum chaperone (SIL1) 
CDC42 small effector 2 
Tyrosine kinase with Ig/EGF homology domains  
Transcription factor 8 
Transforming growth factor beta 1 
Stem cell growth factor 
Suppression of tumorigenicity 13 
R binding motif protein 27 
Tumor necrosis factor, alpha-induced protein 8 
Bone morphogenetic protein 6 
CRI1 
SIL1 
CDC42SE2* 
TIE 
TCF8 
TGFB1 
SCGF 
ST13 
RBM27 
TNFAIP8 
BMP6 
NM_014335 
NM_022464 
AK025620 
NM_005424 
NM_030751 
NM_000660 
NM_002975 
U17714 
AB037732 
NM_014350 
NM_001718 
CREBB/EP300 implicated as tumor suppressor gene 
Located at 5q31; Enhances nucleotide exchange 
Located at 5q23.3; Rho GTPase; regulates actin and kinase signaling 
High expression correlates with shorter survival in CML 
Involved in TGF and BMP signaling 
Multifunctional; proliferation/differentiation, transformation 
Growth factor for primitive hematopoietic stem cells 
Candidate tumor suppressor gene 
Located at 5q32; Unknown function 
Located at 5q23.1; Oncogenic factor in cancer cells 
Secreted signaling protein involved in bone formation 
Down 
Down 
Down 
Down 
Down 
Down 
Down 
Down 
Down 
Down 
Down 
1.5 
1.5 
1.5 
1.4 
1.4 
1.3 
1.3 
1.3 
1.2 
1.1 
0.9 
 
Selected list of genes up- or down-regulated in 5q- (n = 4) CD34
+CD38
-Thy-1
+ candidate HSCs when compared to normal (n = 5) CD34
+CD38
-Thy-1
+ cells (for complete list see 
Supplementary Table 3). *Microarray-based expression validated by Q-PCR. TF indicates transcription factor.  
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Figure legends 
 
  Figure 1. Thy-1 expression within CD34
+CD38
+ progenitor and CD34
+CD38
- stem cell 
compartments in normal and 5q- syndrome BM.  
CD34
 enriched normal (a) and 5q- (b, patient #6) BM cells were stained with MAbs against CD34, 
CD38 and Thy-1 or irrelevant isotype control Abs (Methods). Left panels show expression profiles for 
already CD34 enriched cells with the size of the CD34
+CD38
+ and CD34
+CD38
- populations given as 
percentages of total MNC. Shown are also the gates for CD34
+CD38
+ and CD34
+CD38
- cells used for 
sorting and for further investigation of Thy-1 expression (middle panels). Dotted lines represent the 
negative isotype control and solid lines the specific Thy-1 expression. Note that Thy-1 expression is 
much higher in CD34
+CD38
- than in CD34
+CD38
+ cells for both healthy and 5q- subjects. Sorted 
CD34
+CD38
-Thy-1
+ candidate HSCs and CD34
+CD38
+Thy-1
- candidate progenitors were analyzed by 
FISH for the 5q deletion. Normal CD34
+CD38
-Thy-1
+ cells (a) show two green and two red signals 
while CD34
+CD38
-Thy-1
+ cells with 5q deletion (b) show two green and one red signal (right panels). 
Bars in the FISH pictures represents 10 µm. 
 
Figure 2. Comparison of the global gene expression profiles of normal and 5q- CD34
+CD38
-Thy-
1
+ and CD34
+CD38
+Thy-1
- cell populations. 
(a) Number of genes versus minimal Fisher score for 5q- CD34
+CD38
-Thy-1
+ candidate HSCs when 
compared to normal CD34
+CD38
-Thy-1
+ HSCs (solid line),  normal CD34
+CD38
+Thy-1
- progenitors 
(dashed line), and  5q- CD34
+CD38
+Thy-1
- progenitors (dotted line).  
 (b) Number of differentially expressed genes with Fisher score above 2 for 5q- CD34
+CD38
-Thy-1
+ 
candidate HSCs when compared to normal CD34
+CD38
-Thy-1
+ HSCs, normal CD34
+CD38
+Thy-1
- 
progenitors, and 5q- CD34
+CD38
+Thy-1
- progenitors, respectively. Error bars indicate 95% confidence 
interval [Poisson statistics]. 
 (c) False discovery rate as a function of number of top ranked genes using the Fisher score. Results are 
shown for 5q- CD34
+CD38
-Thy-1
+ candidate HSCs when compared to normal CD34
+CD38
-Thy-1
+ 
HSCs (solid line),  normal CD34
+CD38
+Thy-1
- progenitors (dashed line), and 5q- CD34
+CD38
+Thy-1
- 
progenitors (dotted line). The false discovery rate, i.e. number of accepted genes in a permutation test 
divided by the same number in the correct list, was high when comparing 5q- HSCs with normal HSCs 
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but essentially zero when compared to normal progenitors. A high false discovery rate implies that the 
compared populations do not differ in much more genes than expected by random fluctuations, while a 
low false discovery rate implies significant differences in gene expression between the compared cell 
types, reflecting more extensive differences than expected by random fluctuation. 
 
Figure 3. Quantitative-PCR expression analysis of selected genes in 5q- CD34
+CD38
-Thy-1
+ 
HSCs as compared to normal CD34
+CD38
-Thy-1
+ HSCs.  
 
RNA was isolated from highly purified normal and 5q- CD34
+CD38
-Thy-1
+ cells (Methods) and 
analyzed for quantitative expression of ten genes, selected based on the array analysis. The mean 
expression of 5 healthy subjects (normal; white bars) compared to the mean (grey bars) and individual 
(Patients #1, #2, #4, #6, #7, #8, #9, #10 and #11; black bars) expression of each gene for the 5q- 
syndrome patients normalized against HPRT expression levels. 
 
Figure 4. Comparison of differentially expressed gene expression in MDS stem cells and 
progenitors  
(a) Number of genes versus minimal Fisher scores for 5q- versus normal CD34
+CD38
+Thy-1
- 
progenitors (dashed line) and 5q- versus normal CD34
+CD38
-Thy-1
+ HSCs (solid line), respectively. 
(b) Number of differentially expressed genes with Fisher score above two when comparing  5q- and 
normal CD34
+CD38
-Thy-1
+ stem cells and when comparing 5q- and normal CD34
+CD38
+Thy-1
- 
progenitors. Error bars indicate 95% confidence interval [Poisson statistics]. 
(c) Microarray-based gene expression of ten selected genes in 5q- CD34
+CD38
-Thy-1
+ stem cells and 
5q- CD34
+CD38
+Thy-1
- progenitors relative to the mean expression in their normal counterparts (from 
five healthy subjects and four 5q- patients). [Error bars show SEM]. 
(d)  Q-PCR analysis of CEBPA expression in 5q- CD34
+CD38
-Thy-1
+ stem cells and 5q- 
CD34
+CD38
+Thy-1
- progenitors. Shown are the mean [SEM] differential expression for five healthy 
subjects and nine 5q- patients and individual expression levels for the investigated 5q- patients (#1, #2, 
#4, #6, #7, #8, #9, #10, and #11) normalized against HPRT expression levels. Grey staples for HSCs 
and white staples for progenitors throughout the figure. 
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